沙库巴曲缬沙坦钠片对扩张型心肌病合并慢性心力衰竭患者的临床效果观察

Clinical Effect of Sacubactril Valsartan Sodium Tablets on Patients with Dilated Cardiomyopathy Complicated with Chronic Heart Failure

目的 观察沙库巴曲缬沙坦钠片对扩张型心肌病合并慢性心力衰竭患者的临床效果。方法 选取2020年3月—2021年3月本院收治的62例扩张型心肌病合并慢性心力衰竭患者,遵循随机抽样分组法将其分为参照组和观察组,每组31例。参照组患者运用依那普利治疗,观察组运用沙库巴曲缬沙坦钠片治疗。比较两组患者治疗前和治疗3个月后心功能指标、炎症指标、治疗有效率、用药副作用发生率。结果 治疗前,两组患者心功能指标之间比较差异无统计学意义(P>0.05);治疗后,观察组患者LVEDD、LVEF、NT-proBNP含量好于参照组(P<0.05)。治疗前,两组患者炎症指标之间比较差异无统计学意义(P>0.05);治疗后,观察组患者IL-6、TNF-α低于参照组(P<0.05)。观察组治疗后治疗有效率高于参照组(P<0.05)。观察组用药副作用发生率明显低于参照组(P<0.05)。结论 扩张型心肌病合并慢性心力衰竭患者给予沙库巴曲缬沙坦钠片治疗,可明显改善患者心功能,降低炎症指标水平,提高治疗有效率,降低用药副作用发生率。

Objective To observe the clinical effect of Sakubactril valsartan sodium tablets on patients with dilated cardiomyopathy complicated with chronic heart failure.Methods A total of 62 patients with dilated cardiomyopathy combined with chronic heart failure admitted to our hospital from March 2020 to March 2021 were selected and divided into reference group and observation group according to random sampling grouping,with 31 cases in each group.The reference group was treated with enalapril,and the observation group was treated with sacubactril valsartan sodium tablets.The indexes of cardiac function,inflammation,effective rate and incidence of side effects were compared before treatment and 3 months after treatment between the two groups.Results Before treatment,there was no significant difference in cardiac function indexes between the two groups(P>0.05).After treatment,LVEDD(56.45±3.94)mm,LVEF(49.11±8.75)%and NT-proBNP content(3527.65±332.87)ug/L in observation group were better than those in reference group(P<0.05).Before treatment,there was no significant difference in inflammation indexes between the two groups(P>0.05).After treatment,1L-6(14.62±3.40)ng/L and TNF-a(13.47±2.53)ng/L in observation group were lower than those in reference group(P<0.05).After treatment,the effective rate of treatment in observation group was 96.77%higher than that in reference group 74.19%(P<0.05),and the incidence of side effects in observation group was 3.23%,which was significantly lower than that in reference group(25.81%)(P<0.05).Conclusion In patients with dilated cardiomyopathy complicated with chronic heart failure,the treatment of Sacubactril valsartan sodium tablets can significantly improve the cardiac function of patients,reduce the level of inflammation indicators,increase the treatment efficiency and reduce the incidence of side effects.